Boland Lab - Genevieve M. Boland, MD, PhD
The Boland Lab at Massachusetts General Hospital leads correlative immuno-oncology efforts in melanoma and gastrointestinal malignancies.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
The Boland Lab at Massachusetts General Hospital leads correlative immuno-oncology efforts in melanoma and gastrointestinal malignancies.
Research topics in the Cusack Laboratory include molecular targeted therapies for colorectal cancer, melanoma, Merkel cell cancer and carcinomatosis, and improving delivery of surgical cancer care in resource-limited settings.
The research mission of the Head and Neck Translational Immuno-Oncology Research Lab at Massachusetts General Hospital is to rapidly translate innovative, biomarker-driven immunotherapies that have the potential to improve treatment outcomes for patients with head and neck cancer.
The Laboratory of Gastrointestinal Epithelial Biology works to unravel the molecular mechanisms that underline the processes of growth and differentiation within intestinal epithelia, focusing on gut mucosal defense and how the host interacts with the intestinal microbiota.
The Liss Laboratory in the Division of Gastrointestinal and Oncologic Surgery at Massachusetts General Hospital is interested in understanding the molecular mechanisms that contribute to pancreatic cancer.
The Lubitz Lab focuses on improving the quality of care for patients with thyroid, parathyroid and adrenal disorders.
Research topics in the Maheswaran Lab include tumorigenesis, breast cancer and cancer genetics.
The Oncolytic Virus Laboratory at Massachusetts General Hospital seeks to understand how oncolytic viruses, a new class of tumor immunotherapy or cancer treatment, mediate antitumor activity.
Research topics in the Tanabe Lab include hepatobiliary cancer, epidermal growth factor and hepatocellular carcinoma.
The main focus of the Thyroid Cancer Research Laboratory, led by Sareh Parangi, MD, is to study certain key genetic and epigenetic changes seen more frequently in those patients who do poorly, and find out how exactly these genetic changes lead to more aggressive cancer behavior in those patients.